Glaukos Corp

Insider buying at Glaukos Corp signals CEO confidence in new glaucoma therapies – learn how the 2026 Form 4 filings could boost future upside.

Insider sales at Glaukos Corp show routine portfolio rebalancing; executives keep significant stakes while stock remains volatile with a steep negative P/E.

Insider sell‑off at Glaukos Corp. shows a small, routine liquidity move by CDO Navratil Tomas, not a red flag for investors—focus on FDA milestones and pipeline growth.

Glaukos insider Gilliam Joseph’s dual‑side trade signals confidence in the company’s glaucoma therapy pipeline, balancing gains with long‑term equity buildup.

Insider buy: Hoffmeister David F. purchases 753 Glaukos shares—signals confidence in the company’s glaucoma pipeline and upside potential.

Insider buying surge at Glaukos (GKOS) shows board confidence amid volatile markets, hinting at future upside once product approvals roll out.